Afatinib / Cetuximab combination therapyTrastuzumab / Lapatinib combination therapyEverolimus / Letrozole combination therapyPanitumumab / Dabrafenib / Trametinib combination therapyCabozantinib / Panitumumab combination therapySorafenib / Sirolimus combination therapyCetuximab / Sirolimus combination therapyTrametinib / Ponatinib combination therapyEverolimus / Bevacizumab combination therapyEverolimus / Erlotinib combination therapyEverolimus / Pazopanib combination therapyVeliparib / Cisplatin combination therapyVemurafenib / Cobimetinib combination therapyCrizotinib / Trastuzumab combination therapySirolimus / Erlotinib combination therapyTretinoin / Arsenic Trioxide combination therapyDabrafenib / Trametinib combination therapyCrizotinib / Vemurafenib combination therapyPanitumumab / Trametinib combination therapyAfatinib / Nimotuzumab combination therapyVemurafenib / Panitumumab combination therapyTrametinib / Imatinib combination therapyLapatinib / Afatinib combination therapyErlotinib / Cetuximab combination therapyEverolimus / Octreotide combination therapyVinblastine / Nilotinib combination therapyVenetoclax / Bortezomib combination therapyPanitumumab / Dabrafenib / BYL719 combination therapyDasatinib / Venetoclax combination therapyMK2206 / Trastuzumab combination therapyPLX4720 / GDC0941combination therapyPLX4720 / Nutlin-3 combination therapyCapecitabine / Vemurafenib / Bevacizumab combination therapyTrametinib / PD0325901 combination therapyDacarbazine / Temozolomide combination therapyPLX4720 / GDC0941 combination therapyCetuximab / Panitumumab combination therapyVemurafenib / Gefitinib / Cetuximab combination therapyTrametinib / Dabrafenib combination therapyBEZ235 (NVP-BEZ235, Dactolisib) / GDC-0879 combination therapy
P31
P366
P461
Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential HypertensionClinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CA Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CDurability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DMOpen-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV StudiesSofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV InfectionSofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV InfectionNIDDM and IR in Combination Therapy for CHCSitagliptin in Combination With Metformin and SulfonylureaStudy to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid TumorsStudy of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AMLSofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and reviewMonotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan CilexetilA Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive BladderLedipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV InfectionEffects of Home-based Mirror Therapy Combined With Task-oriented Training for Patients With StrokeDose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell CarcinomaClinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical TrialEvaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's DiseaseSafety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus InfectionA proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination TherapySafety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung CancerSofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential HypertensionSafety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 SubjectsSafety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCVClinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan Dose Response Clinical TrialGS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) InfectionGS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) InfectionPhase I Trial of Combination of FOLFIRI and SOM 230Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric SubjectsCombination of Nicotine Replacement Therapy (NRT) and Varenicline to Increase Cessation of Tobacco (CONVICT Study)Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic ArthritisCombination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective AnalysisSofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take InterferonValsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic HypertensionSafety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors
P921
Q38159991-35B4E75F-A1F7-4675-A753-EA8833F822D5Q38160367-1B817D46-C20A-49AF-8719-65141B581DFBQ38160408-DFB22023-F80F-4543-8636-F3D4415CAF81Q38160409-E401AAB4-CA2C-48D8-B4FA-2E936E0B3585Q38160411-097C49E9-20E0-4F09-B1A8-3BC868D71E1FQ38160412-2CB239A7-DB08-48FB-A37D-13B2528B4AE8Q38160413-4D02E440-2C31-49C1-B2D4-67EC8DC21EF4Q38160414-961AD710-C0D9-4543-B7E6-611F97B3D85EQ38160416-D15B87E5-1758-4A12-9348-20653E0ABFF7Q38160417-2E8D9C7C-F785-45E7-B5CF-899859B84F74Q38160418-AD240AE1-D325-4DE4-B38F-A8E1BFCD77D3Q38160420-6DAD45ED-BAF3-40F3-B9C8-6AC7EFDBEBCBQ38160422-A6F3E45E-6E04-455F-A97D-2A77771EF2A8Q38160423-ED5FBDCE-D303-4DAE-826D-AA6CD8B12C29Q38160424-B8B6A264-4B63-42EF-816B-5689D96317F2Q38160425-1C73A283-09EC-4986-B654-399087AB06B3Q38160427-3DFDF41E-DC9A-4195-9EEB-DCFA8F1A62A8Q38160428-52A209BD-72A9-4C93-945A-CEB9577AD652Q38160429-716820F8-7BA2-4654-9FE4-D37FCC1A8D05Q38160430-FF31C5B9-0607-483B-95C8-9580896EECCAQ38160432-D2E7FFE8-BE29-445A-AA64-5AD09C1C84B1Q38160433-D06354D9-41A6-48C2-A681-C0A60B6D3764Q38160434-B8FA382B-2299-4351-8406-444CC119ECF6Q38160435-960B60AF-55A8-4755-AA32-5E8DD158E11DQ38195399-AF39ABAA-9ED1-47FB-8692-028DE01A93EEQ38195401-27711058-B2A0-430F-B5F6-2B619DBE9EF7Q38195402-D2F3786F-EB75-4756-BD58-B173D8740F1AQ38195403-2AA4E30D-753F-4320-84E2-DCAC6B339C36Q38195405-FF6C21A2-10C0-4F7D-94BD-8D6A6A60CFEDQ38195406-FFAEDD29-E1A5-4EEC-BCEF-1EB24E975674Q38832586-f4818178-4bef-1436-9a12-724537709bcaQ38833097-2fe95df5-42cc-389d-4fdc-6e3cd057b4c5Q38836200-e3a07881-43fd-80fe-1deb-3375ef5afebaQ38932908-71f216d1-4ee8-8237-a26d-663438700314Q39136123-B75CFB87-DEBE-44E3-94EB-6E17FBE608AFQ39136127-349B2D29-BF39-4816-A830-9FF334B0A1B2Q39136131-9E608432-D6EA-4BED-92B5-2C46E3B8EA7BQ39136135-4E49839C-F98F-4CC8-9484-73F4B03F12CDQ39136138-BC3A39F5-68F3-4095-B2E7-EC5585B4E2A4Q39136143-F0E1AA05-0058-4F6C-A116-99F97A911BE1
P31
description
die Behandlung einer Erkrankung mit zwei oder mehr Arzneistoffen
@de
l'utilisation de plusieurs médicaments différents pour traiter un seul désordre
@fr
terapio uzanta plurajn medikamentojn, ekz. por aidoso aŭ malario
@eo
the use of several medications ...... ticularly HIV/AIDS and malaria
@en
the use of several medications ...... ticularly HIV/AIDS and malaria
@en-gb
name
Kombinationstherapie
@de
Politerapia
@it
Politerapia
@pl
combination therapy
@en
combination therapy
@en-gb
plurterapio
@eo
polythérapie
@fr
Điều trị đa mô thức
@vi
علاج مركب
@ar
単剤療法
@ja
type
label
Kombinationstherapie
@de
Politerapia
@it
Politerapia
@pl
combination therapy
@en
combination therapy
@en-gb
plurterapio
@eo
polythérapie
@fr
Điều trị đa mô thức
@vi
علاج مركب
@ar
単剤療法
@ja
altLabel
Kombitherapie
@de
combination drug therapy
@en
kombinita terapio
@eo
medical polytherapy
@en
medical polytherapy
@en-gb
polytherapy
@en
polytherapy
@en-gb
併用療法
@ja
prefLabel
Kombinationstherapie
@de
Politerapia
@it
Politerapia
@pl
combination therapy
@en
combination therapy
@en-gb
plurterapio
@eo
polythérapie
@fr
Điều trị đa mô thức
@vi
علاج مركب
@ar
単剤療法
@ja
P486
P6366
P672
P279
P31
P3417
Combination-Therapy
P486
P6366
2776999253
P672
E02.319.310